Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-03, Stock:NVS, The news for the past five days is as follows:
2019-03-27: NEWS1: Novartis (NVS) Receives FDA Approval for MS Drug Mayzent.NEWS2: Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study.NEWS3: Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study.NEWS4: Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study.NEWS5: The Hits Just Keep Coming For Biogen As Rival Gains MS Drug Approval.NEWS6: Novartis MS drug wins FDA's blessing amid scrutiny of $88k annual price.NEWS7: 6 Gene Therapy M&A Targets On The Radar.NEWS8: Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod.NEWS9: FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis.NEWS10: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO.NEWS11: Novartis new MS drug Mayzent to be priced at $88,000 per year.NEWS12: Novartis gets U.S. approval for new drug to treat multiple sclerosis.
2019-03-28: NEWS1: Achillion Completes Enrollment in Rare Blood Disorder Study.NEWS2: Achillion Completes Enrollment in Rare Blood Disorder Study.NEWS3: Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?.NEWS4: Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?.NEWS5: AbbVie's big acquisition blowup: A one-off or an omen?.NEWS6: Novartis (NVS) Receives FDA Approval for MS Drug Mayzent.NEWS7: Novartis (NVS) Receives FDA Approval for MS Drug Mayzent.
2019-03-29: NEWS1: NASH Scorecard So Far This Year: A Look at the Hits & Misses.NEWS2: NASH Scorecard So Far This Year: A Look at the Hits & Misses.NEWS3: Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals.NEWS4: Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals.NEWS5: Global Blood Focuses on Developing Lead Candidate Voxelotor.NEWS6: Global Blood Focuses on Developing Lead Candidate Voxelotor.
2019-04-01: NEWS1: Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics.NEWS2: Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics.NEWS3: Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics.NEWS4: Novartis Snags A $1.6 Billion Buy That Could Rival These Biotechs.NEWS5: Novartis Announces $1.575B Acquisition Of IFM Tre.NEWS6: Swiss drugmaker Novartis must face doctor kickback suit, U.S. judge rules.NEWS7: BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?.NEWS8: BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?.NEWS9: BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?.NEWS10: Novartis to pay $310 million for assets from inflammation specialist IFM.NEWS11: Novartis scoops up IFM immunotherapy subsidiary for $310 million.
2019-04-02: NEWS1: Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe.NEWS2: Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe.NEWS3: Novartis Gets Approval for Psoriasis Drug Cosentyx in China.NEWS4: Novartis Gets Approval for Psoriasis Drug Cosentyx in China.NEWS5: Novartis Gets Approval for Psoriasis Drug Cosentyx in China.NEWS6: Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe.NEWS7: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial.

Answer: Rise